Lai 2019.

Methods	Study design: Randomised clinical trial Study duration: March 2017 to March 2018 Duration of follow‐up: 3 weeks Setting: Hospital
Participants	Number of participants: 32 Inclusion criteria: Diagnosed as HCC; expected survival time ≥ 3 months
Interventions	TACE + MWA group (n = 24): TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: carboplatin 300 mg, and epirubicin 30 mg MWA: The interval between TACE and MWA was 1–3 weeks. Control group (n = 8): TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: carboplatin 300 mg, and epirubicin 30 mg
Outcomes	Immunological function (CD3, CD4, CD8, and NK cell): measured by blood testing
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.